Thailand Pharmaceuticals & Healthcare Report

Published 29 July 2015

  • 115 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
$1,295.00
Thailand Pharmaceuticals & Healthcare Report

BMI View: Thailand's medical system will see a transformation. This comes as there is a growing divergence between the three healthcare schemes in the country in terms of cost as well as healthcare outcomes. In addition, the economy has taken a much stronger precedence under the new military government which will curtail additional funding towards Thailand's healthcare programmes despite the schemes' growing financial constraints. This change could have negative ramifications for drugmakers and healthcare providers - especially should the shift be towards a central agency that negotiates prices for all three programmes.

Headline Expenditure Projections

  • Pharmaceuticals: THB145.5bn (USD4.5bn) in 2014 to THB152.9bn (USD4.6bn) in 2015; +5.1% in local currency terms and +2.7% in US dollar terms.

  • Healthcare: THB581.7bn (USD17.9bn) in 2014 to THB621.3bn (USD18.6bn) in 2015: +6.8% in local currency and +4.3% in US dollar terms.

Risk/Reward Index

In Q415, Thailand remains ranked roughly in the middle of the Pharmaceutical RRI table that assesses the attractiveness of the 19 countries in the Asia Pacific region. This is because while Thailand remains relatively attractive to pharmaceutical investors with its growing pharmaceutical sector, its overall score is dragged down by the risks, including low levels of patent protection that is imposed on drugmakers. As such it scores 16.3 out of a total of 35 on its risk score, significantly below the regional average of 19.5.

Key Trends & Developments

  • In May 2015, Thailand's Prime Minister Prayut Chain-cha instructed the ministries in charge of public health and commerce to set standard median prices for medical care at private hospitals. Critically, authorities are to ensure that the difference in prices between the private healthcare providers and public hospitals do not remain too large.

  • In June 2015, Thailand reported its first confirmed case of the Middle East respiratory syndrome (MERS). This prompted the...

BMI Industry View
7
SWOT
9
Political
11
Economic
12
Operational Risk
13
Industry Forecast
15
Pharmaceutical Market Forecast
15
Table: Pharmaceutical Sales, Historical Data And Forecasts (Thailand 2011-2019)
16
Healthcare Market Forecast
17
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Thailand 2011-2019)
19
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Thailand 2011-2019)
20
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Thailand 2011-2019)
20
Prescription Drug Market Forecast
20
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Thailand 2011-2019)
22
Patented Drug Market Forecast
22
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Thailand 2011-2019)
24
Generic Drug Market Forecast
24
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Thailand 2011-2019)
26
OTC Medicine Market Forecast
26
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Thailand 2011-2019)
28
Pharmaceutical Trade Forecast
28
Table: Pharmaceutical Trade Data And Forecasts (Thailand 2013-2019)
31
Table: Pharmaceutical Trade Data And Forecasts local currency (Thailand 2013-2019)
31
Key Risks To BMI's Forecast Scenario
32
Macroeconomic Forecasts
33
Economic Analysis
33
Table: Economic Activity (Thailand 2010-2019)
37
Industry Risk Reward Index
38
Asia Pacific Risk/Reward Index
38
Thailand Risk/Reward Index
44
Rewards
44
Risks
44
Market Overview
46
Industry Trends And Developments
47
Epidemiology
47
Table: Estimated Number Of New Cases Of Cancer In Thailand
50
Healthcare System
50
Healthcare Insurance
51
Recent Health Insurance Developments
53
Table: Healthcare Resources (Thailand 2009-2014)
55
Table: Healthcare Personnel (Thailand 2009-2014)
55
Table: Healthcare Activity (Thailand 2009-2014)
56
Medical Tourism
56
Research And Development (R&D)
59
Biosimilars
61
Clinical Trials
61
Regulatory Development
64
Regulatory Regime
64
Regulatory Development
65
Regional Harmonisation
66
Intellectual Property Regime
67
IP Developments
67
Pricing
68
Table: Price Build-Up Of Medicines In Thailand
69
Reimbursement
69
Competitive Landscape
71
Research Based Industry
71
Table: PReMA Members
71
Recent Pharmaceutical Industry Developments
72
Domestic Pharmaceutical Industry
73
Table: Pharmaceutical Manufacturers Of Modern Drugs, 2007-2012
74
Pharmaceutical Wholesale
74
Pharmaceutical Retail
76
Company Profile
78
Siam Pharmaceutical
78
Government Pharmaceutical Organisation
80
Biolab
84
Thai Meiji Pharmaceutical Company
86
Berlin Pharmaceutical Industry
88
Pfizer
91
Sanofi
94
GlaxoSmithKline
97
Merck & Co
100
Novartis
103
Demographic Forecast
106
Table: Population Headline Indicators (Thailand 1990-2025)
107
Table: Key Population Ratios (Thailand 1990-2025)
107
Table: Urban/Rural Population & Life Expectancy (Thailand 1990-2025)
108
Table: Population By Age Group (Thailand 1990-2025)
108
Table: Population By Age Group % (Thailand 1990-2025)
109
Glossary
111
Methodology
113
Pharmaceutical Expenditure Forecast Model
113
Healthcare Expenditure Forecast Model
113
Notes On Methodology
114
Risk/Reward Index Methodology
115
Index Overview
116
Table: Pharmaceutical Risk/Reward Index Indicators
116
Indicator Weightings
117

The Thailand Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Thailand Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Thailand pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's pharmaceutical and healthcare market forecasts for Thailand, to test other views - a key input for successful budgeting and strategic business planning in the Thai pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Thai pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Thailand.
  • Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

Coverage

BMI Industry View

An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis, and taken together with BMI’s political, economic and business environment SWOTs, it gives a complete overview of market climate.

BMI Industry Forecast Scenario

Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:

  • Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per ‘000 population).
  • Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD).
  • Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
  • Generic Drug Market: Generic product sales (USDbn), generic sales (% of total sales).
  • OTC Drug Market: OTC sales (USDbn & % of total sales).
  • Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against USD, government expenditure and external debt.

BMI’s Pharmaceuticals and Healthcare Risk Reward Index

BMI’s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market’s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry, economic and demographic data points to provide indices of highest to lowest appeal to investors, with each position explained.

Market Summary

A snapshot of key market characteristics, including total size of the pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape

Industry Developments

A focus on government healthcare reforms, epidemiological trends, mergers and acquisitions, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as analysis of the overall regulatory burden.

Competitive Landscape

The competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales – for the total pharmaceutical sector, as well as the OTC, generics and distribution sub-sectors.

Company Profiles*

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI’s industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

*Company profiles are not available for every country. Those reports instead contain information on the current activities of prominent companies operating in the market.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%